INTEGRA BENZODIAZEPINE 737984

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 05 report with the FDA on 2001-09-05 for INTEGRA BENZODIAZEPINE 737984 manufactured by Roche Diagnostics.

Event Text Entries

[210512] Benzodiazepine semi-quantitative assay gave a negative result, but retest with gcms gave a result of 53,000 ng/ml of lorazepam.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number1823260-2001-00182
MDR Report Key350577
Report Source05
Date Received2001-09-05
Date of Report2001-08-23
Date of Event2001-07-27
Date Mfgr Received2001-07-27
Device Manufacturer Date2001-01-01
Date Added to Maude2001-09-12
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag0
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactDEBARA REEK
Manufacturer Street9115 HAGUE RD.
Manufacturer CityINDIANAPOLIS IN 46250
Manufacturer CountryUS
Manufacturer Postal46250
Manufacturer Phone3175763857
Manufacturer G1*
Manufacturer Street*
Manufacturer City*
Manufacturer Country*
Single Use3
Remedial ActionOT
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameINTEGRA BENZODIAZEPINE
Generic NameIN-VITRO DIAGNOSTIC REAGENT
Product CodeJXM
Date Received2001-09-05
Model NumberNA
Catalog Number737984
Lot Number157199
ID NumberNA
Device Expiration Date2002-07-31
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device AgeNA
Device Eval'ed by MfgrR
Implant FlagN
Date RemovedA
Device Sequence No1
Device Event Key339872
ManufacturerROCHE DIAGNOSTICS
Manufacturer Address9115 HAGUE RD. INDIANAPOLIS IN 46250 US
Baseline Brand NameINTEGRA BENZODIAZEPINE
Baseline Generic NameNA
Baseline Model NoNA
Baseline Catalog No737984
Baseline IDNA
Baseline Device FamilyINTEGRA FAMILY OF ANALYZERS
Baseline Shelf Life Contained*
Baseline Shelf Life [Months]*
Baseline PMA FlagN
Baseline 510K PMNY
Premarket NotificationK951595
Baseline PreamendmentN
Baseline TransitionalN
510k ExemptN


Patients

Patient NumberTreatmentOutcomeDate
101. Other 2001-09-05

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.